Kinnate Biopharma Inc.
12707 High Bluff Drive
Suite 200
San Diego
CA
92130
United States
37 articles with Kinnate Biopharma Inc.
-
Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates
5/12/2022
Kinnate Biopharma Inc. announced financial results for the quarter ended March 31, 2022.
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248
4/18/2022
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the first patient has commenced treatment in its Phase 1 KN-4802 (NCT05242822) clinical trial evaluating its lead Fibroblast Growth Factor Receptor (FGFR) product candidate, KIN-3248.
-
Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting
4/8/2022
Kinnate Biopharma Inc. announced that it will present data from the company’s lead RAF kinase inhibitor program, KIN-2787, and its clinico-genomics study investigating the occurrence of BRAF Class II and Class III alterations across solid tumors.
-
Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates
3/28/2022
Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced financial results for the full year ended December 31, 2021.
-
Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting
3/8/2022
Kinnate Biopharma Inc. announced abstracts highlighting the company’s lead RAF kinase inhibitor program, KIN-2787, have been accepted for presentation at the upcoming American Association for Cancer Research Annual Meeting 2022, to be held April 8-13, in New Orleans, Louisiana.
-
Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress
3/7/2022
Kinnate Biopharma Inc. announced the presentation of findings from a collaborative study with Tempus investigating the prevalence of Class II and Class III alterations among patients with BRAF-mutated solid tumors.
-
Kinnate Biopharma Inc. to Participate in the 42nd Annual Cowen Health Care Conference
2/28/2022
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will provide a company overview at the 42nd Annual Cowen Health Care Conference.
-
Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting
2/14/2022
Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced that it has been selected to deliver an oral presentation of preclinical data from its KIN-2787 program at the upcoming virtual IASLC 2022 Targeted Therapies of Lung Cancer meeting taking place February 22-26, 2022.
-
Kinnate Biopharma Inc. to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2/7/2022
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will provide a company overview at the 11th Annual SVB Leerink Global Healthcare Conference.
-
The funds will be used to advance the firm's precision oncology research efforts and pipeline, particularly those involving the creation of alteration-specific therapies.
-
Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium
1/19/2022
Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the presentation of updates from preclinical studies evaluating its Fibroblast Growth Factor Receptor inhibitor candidate, KIN-3248.
-
Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248Planned initiation of Phase 1 clinical trial for KIN-3248 in 1H2022
1/18/2022
Kinnate Biopharma Inc. today announced that the U.S Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for KIN-3248.
-
Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones
1/6/2022
Kinnate Biopharma Inc. announced continued advancement of the company’s ongoing clinical trial, KN-8701, to include patients with NRAS-mutant melanoma and planned 2022 milestones for its product candidates, including KIN-2787, an orally available small molecule pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors.
-
Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scientific Meetings
12/20/2021
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), today announced that the company will present at two upcoming scientific meetings, the AACR Special Conference: Targeting RAS, being held January 7-10, 2022 in Lake Buena Vista, Florida and the ASCO GI Cancers Symposium, being held January 20-22 in San Francisco, California.
-
Kinnate Biopharma Inc. Announces Addition to NASDAQ Biotechnology Index
12/16/2021
Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced that it has been selected for addition to the NASDAQ Biotechnology Index.
-
Kinnate Biopharma Inc. Reports Third Quarter 2021 Financial Results
11/10/2021
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the quarter ended September 30, 2021.
-
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences - Nov 08, 2021
11/8/2021
Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced that its Chief Executive Officer Nima Farzan will provide a company overview at the following upcoming investor conferences in November.
-
Kinnate Biopharma Inc. in Collaboration with Guardant Health Announces Initial Findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study
11/1/2021
Kinnate Biopharma Inc. today announced a collaboration with Guardant Health, a leading precision oncology company, focused on characterizing the prevalence of patients with advanced solid tumors bearing BRAF Class I, II and III alterations.
-
Kinnate Biopharma Inc. Announces Transition of Chief Scientific Officer
10/28/2021
Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced that the company’s Chief Scientific Officer, Eric Murphy, Ph.D., will step down from that role on December 3, 2021 to pursue a new opportunity.